Search bioRxiv⌕ Search

Biology subjects

Leddy, J.

Publications and source records attributed to Leddy, J..

2 recordsLinked to original sources

A deep learning approach to neurite prediction in high throughput fluorescence imaging

Changes to neuronal morphology and loss of neurites and synaptic connections can be an important early indicator of neurological diseases, and a pathognomonic sign of neurodevelopmental disorders. These changes are typically detectable by microscopy in cell culture or histological samples, but quantification can be challenging. The neurites extending from cell soma can be quite thin, dim, overlapping and complex, making them laborious to trace manually and difficult to annotate and quantify computationally or automatically. Moreover, the tools available to aid this aim are limited in their capacity to generalize to high throughput image acquisition such as time-lapse or longitudinal imaging, where imaging conditions can change dramatically over the course of the experiment. In order to facilitate neurite quantification, we developed a deep learning (DL) neurite annotation prediction algorithm (NAPA) to predict the structure and length of neurites. NAPA overcomes experimental variation inherent to fluorescence imaging by learning more broader features that are important for neurite recognition. Based on a dataset with partial annotation, NAPA generated predictions on several unannotated datasets, and was able to capture differences between disease and control conditions. We also defined a sequence of steps to generate custom models with a small number of annotation inputs, and extended the predictions to a 3D tissue sample and longitudinal imaging. With this algorithm we developed an approach to quantify neurites with an accuracy that nears and sometimes exceeds human curation, in 1/100th of the time. This approach makes accurate analysis of large or longitudinal datasets feasible across a broad range of datasets.

neuroscience↗

Improving Proteinuria Screening with Mailed Smartphone Urinalysis Testing in Previously Unscreened Patients with Hypertension: a Randomized Controlled Trial

BackgroundProteinuria screening is recommended for patients with hypertension to screen for kidney disease and identify those at elevated risk for cardiovascular disease. However, screening rates among hypertensive patients are low. Home testing strategies may be useful in improving proteinuria screening adherence. MethodsWe conducted an individual-level, randomized trial at 55 primary care clinic sites in the Geisinger Health System to evaluate the effectiveness of a strategy using home smartphone urinalysis test (Dip.io) to complete proteinuria screening in previously unscreened non-diabetic patient portal users with hypertension. All patients received an educational letter and a standing urinalysis lab order, and then were randomized to control (usual care) or intervention. Intervention arm participants were invited to complete proteinuria screening with a mailed home smartphone urinalysis test. Co-primary outcomes were completion of proteinuria screening and number of albuminuria cases (albumin/creatinine ratio [ACR] [&ge;] 30 mg/g or protein/creatinine ratio [&ge;] 150 mg/g) at the end of 3 months. We also evaluated patient satisfaction with the home test, and compliance with recommendations for patients with newly detected albuminuria. ResultsA total of 999 patients were randomized to intervention or control. Out of 499 patients assigned to the intervention arm, 253 were reached by phone, and 69/97 (71.1%) consented patients completed the home test. Overall, the intervention increased proteinuria screening completion (28.9% vs. 18.0%; p<0.001) with no effect on the number of albuminuria cases (4 vs. 4) although only 6/57 (10.5%) patients with trace or 1+ urine dipstick protein had a follow-up quantitative test. Among the 55 patients who completed a survey after the home test, 89% preferred testing at home rather than the physicians office. ConclusionsA strategy using a home urinalysis smartphone test increased proteinuria screening rates in previously unscreened patients with hypertension and may be useful in increasing rates of proteinuria screening compliance. Future studies are needed to determine whether improving early detection of kidney disease can improve future kidney health. Trial RegistrationClinical Trial Registry: NCT03470701 https://clinicaltrials.gov/ct2/show/NCT03470701

clinical trials↗